Treating abdominal pain due to pancreatitis with seaprose
AssigneeAltus Pharmaceuticals Inc.
InventorsAlexey L. Margolin, Bhami C. Shenoy, Margaret McGrath
Life of this patent
Estimating the term…
Abstract
This invention relates to methods for maintaining the basal level or reducing the level of cholecystokinin (CCK) in blood plasma of a mammal. Additionally, the invention provides methods for treating pain in a mammal and more particularly, methods for treating abdominal pain in a mammal. The methods include administering to the mammal a non-pancreatic protease or a composition comprising a non-pancreatic protease. The methods of this invention are particularly useful for treating abdominal pain in a mammal suffering from acute or chronic pancreatitis and related conditions.
Claims58
A method for treating abdominal pain in a mammal due to pancreatitis, the method comprising administering seaprose to said mammal.
A method for treating abdominal pain in a mammal due to pancreatitis, the method comprising the step of administering seaprose to said mammal, wherein the plasma cholecystokinin (CCK) level in said mammal after administering said seaprose is less than or at the same level as a plasma cholecystokinin (CCK) level in said mammal before administering said seaprose and remains less than or at the same level as the plasma cholecystokinin (CCK) level in said mammal before administering said seaprose for a period of time selected from the group consisting of:
- (a) between zero and about 4 hours after administering said seaprose;
- (b) between zero and about 8 hours after administering said seaprose;
- and
- (c) between zero and about 12 hours after administering said seaprose.
A method for treating abdominal pain in a mammal due to pancreatitis, the method comprising the step of administering seaprose to said mammal, wherein said seaprose causes a reduction in maximum plasma concentration (Cmax) of cholecystokinin (CCK) in said mammal as measured by comparing (a) said Cmax in the absence of said seaprose after food administration to (b) said Cmax in the presence of said seaprose after food administration, and wherein said reduction is selected from the group consisting of:
- (i) at least about 10% to about 25% reduction;
- (ii) at least about 25% to about 50% reduction;
- (iii) at least about 50% to about 75% reduction;
- and
- (iv) at least about 75% to about 100% reduction.
A method for treating abdominal pain in a mammal due to pancreatitis, the method comprising the step of administering seaprose to said mammal, wherein said seaprose reduces the plasma cholecystokinin (CCK) level in said mammal as compared to the plasma cholecystokinin (CCK) level in said mammal before administering said seaprose.
A method for treating abdominal pain in a mammal due to pancreatitis, the method comprising administering seaprose to said mammal with food, wherein said seaprose reduces the maximum plasma concentration (Cmax) of CCK in said mammal as compared to the Cmax of CCK in said mammal without said seaprose being present during administration of food.
Dependencies are inferred from the claim text.